Shots:

• The approval is based on P-lll DISCOVER-1 & -2 study assessing Tremfya (100mg q4w and q8w) vs PBO in 381 & 739 patients with active PsA who had an inadequate response to SOC &
• Who were biologic-naïve only and had an inadequate response to SOC respectively
• Combined results: achieved 1EPs of ACR20 @24wks.; improvements in quality of life scores; improvement in PASI 75- PASI 90- and PASI 100 rates. In DISCOVER-2 study- @24wks. less radiographic progression in both groups Tremfya is the first selective IL-23 p19 subunit inhibitor licensed for both the treatment of PsA and PsO

 ­ Ref: Janssen | Image: Janssen